NCT02841904

Brief Summary

This study evaluates the accuracy of Confocal Laser Endomicroscopy (CLE) in the diagnostic of non-invasive flat and exophytic bladder neoplasia. CLE results are compared to histopathology results.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
189

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jun 2018

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 7, 2016

Completed
15 days until next milestone

First Posted

Study publicly available on registry

July 22, 2016

Completed
1.9 years until next milestone

Study Start

First participant enrolled

June 1, 2018

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2019

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2019

Completed
Last Updated

March 6, 2018

Status Verified

March 1, 2018

Enrollment Period

1.3 years

First QC Date

July 7, 2016

Last Update Submit

March 5, 2018

Conditions

Outcome Measures

Primary Outcomes (2)

  • accordance between CLE and histology in flat bladder tumors

    Accordance between confocal laser endoscopy and conventional biopsy according to the evaluation of the pathologist in flat bladder neoplasia

    An average of 18 months

  • Accordance between CLE and histology in exophytic bladder tumors

    Accordance between confocal laser endoscopy and conventional biopsy according to the evaluation of the pathologist in exophytic bladder neoplasia

    An average of 18 months

Secondary Outcomes (2)

  • Accordance between CLE assessed by the surgeon and histology.

    An average of 18 months

  • Accordance between the per-operative evaluation of CLE of the pathologist and the surgeon

    An average of 18 months

Study Arms (2)

CLE

OTHER

CLE assessed by the pathologist

Device: Confocal LASER Endomicroscopy

Biopsy

ACTIVE COMPARATOR

Histology assessed by the pathologist

Device: Confocal LASER Endomicroscopy

Interventions

Patients scheduled for bladder endoscopic surgery under general anesthesia are offered to be included in our study. The suspicious mucosal areas are marked then examined with CLE. Tissue samples are taken based on the usual standard criterias. The samples are evaluated microscopically and compared with the results of the CLE technique. A single surgeon performs all surgeries. Biopsies are anlysed by a pathologist from Herlev and Gentofte Hospital's Pathology Department, which is affiliated CLE- study.

Also known as: Cellvisio
BiopsyCLE

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • First time Transurethral Resection of Bladder (TURB) for bladder tumors under 3 cm
  • Suspicious mucosa / Carcinoma in situ
  • Recurrent pTa
  • Positive cytology with normal flexible cystoscopy
  • Control after Bacille Calmette Guérin (BCG) treatment

You may not qualify if:

  • Allergy to fluorescein
  • Pregnant and lactating women.
  • Renal failure (eGFR \<20 ml / min)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Urology department

Herlev, 2730, Denmark

Location

MeSH Terms

Conditions

Urinary Bladder Neoplasms

Condition Hierarchy (Ancestors)

Urologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteNeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesUrinary Bladder DiseasesUrologic DiseasesMale Urogenital Diseases

Study Officials

  • Sami Beji, MD

    Herlev Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Mette Ladefoged Kopp Schmidt

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Medical doctor

Study Record Dates

First Submitted

July 7, 2016

First Posted

July 22, 2016

Study Start

June 1, 2018

Primary Completion

September 1, 2019

Study Completion

December 1, 2019

Last Updated

March 6, 2018

Record last verified: 2018-03

Data Sharing

IPD Sharing
Will not share

Locations